News

Lucentis (ranibizumab) has now been cleared to treat patients for visual impairment due to CNV associated with causes other than neovascular age-related macular degeneration (nAMD) or secondary to

The study found that patients with ALK+ advanced NSCLC treated with first-line Zykadia (ceritinib) had a median progression-free survival (PFS) of 16.6 months (95% confidence interval [CI]: 12.6, 27.2), compared to

Women are said to have a ‘platinum-sensitive’ form of the disease if a relapse occurs six months or longer following the last treatment with a platinum-based chemotherapy. Genentech

Velusetrag is an oral investigational drug in development for the treatment of patients with gastroparesis, and is currently being studied in a large, multinational Phase 2b study in

The Competition and Markets Authority (CMA) fined Pfizer £84.2m and Flynn Pharma £5.2m after they increased prices by as much as 2,600% in September 2012. Due to the price increases, the

Results from the first randomised Phase III data showed that Tagrisso reduced the risk of lung cancer progression by 70% compared to chemotherapy and improved progression-free survival (PFS)

The goal of the collaboration is to accelerate Purdue’s Nav1.7 sodium ion channel drug candidates utilizing AnaBios’ Phase-X discovery platform to develop treatments for chronic pain. Under the terms

Data from this study is expected to be announced in the first half of 2017.  MAT2501 is Matinas BioPharma’s orally-administered, encochleated formulation of the broad spectrum IV-only aminoglycoside

LOJUXTA, marketed as JUXTAPID in the United States, is currently approved by the European Commission as an adjunct to a low-fat diet and other lipid-lowering medicinal products with or without low